IL326358A - Rna compositions encoding herpes simplex virus glycoprotein e and/or glycoprotein i antigens and uses thereof - Google Patents

Rna compositions encoding herpes simplex virus glycoprotein e and/or glycoprotein i antigens and uses thereof

Info

Publication number
IL326358A
IL326358A IL326358A IL32635826A IL326358A IL 326358 A IL326358 A IL 326358A IL 326358 A IL326358 A IL 326358A IL 32635826 A IL32635826 A IL 32635826A IL 326358 A IL326358 A IL 326358A
Authority
IL
Israel
Prior art keywords
glycoprotein
antigens
herpes simplex
simplex virus
rna compositions
Prior art date
Application number
IL326358A
Other languages
Hebrew (he)
Original Assignee
Univ Pennsylvania
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US18/365,166 external-priority patent/US20240016922A1/en
Application filed by Univ Pennsylvania, BioNTech SE filed Critical Univ Pennsylvania
Publication of IL326358A publication Critical patent/IL326358A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL326358A 2023-08-03 2024-08-02 Rna compositions encoding herpes simplex virus glycoprotein e and/or glycoprotein i antigens and uses thereof IL326358A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363517581P 2023-08-03 2023-08-03
US18/365,166 US20240016922A1 (en) 2017-08-17 2023-08-03 Rna vaccines encoding herpes simplex virus glycoproteins and uses thereof
US202463670048P 2024-07-11 2024-07-11
PCT/US2024/040788 WO2025030134A1 (en) 2023-08-03 2024-08-02 Rna compositions encoding herpes simplex virus glycoprotein e and/or glycoprotein i antigens and uses thereof

Publications (1)

Publication Number Publication Date
IL326358A true IL326358A (en) 2026-04-01

Family

ID=92543442

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326358A IL326358A (en) 2023-08-03 2024-08-02 Rna compositions encoding herpes simplex virus glycoprotein e and/or glycoprotein i antigens and uses thereof

Country Status (4)

Country Link
CN (1) CN121866069A (en)
AU (1) AU2024318951A1 (en)
IL (1) IL326358A (en)
WO (1) WO2025030134A1 (en)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4998993A (en) 1992-08-07 1994-03-03 Epimmune, Inc. Hla binding peptides and their uses
CN1118572A (en) 1993-03-05 1996-03-13 萨依特尔有限公司 HLA-A2.1 combination peptide and its use
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
ATE490267T1 (en) 2001-06-05 2010-12-15 Curevac Gmbh STABILIZED MRNA WITH INCREASED G/C CONTENT CODING A VIRAL ANTIGEN
EP3611266B1 (en) 2005-08-23 2022-11-09 The Trustees of the University of Pennsylvania Rna containing modified nucleosides and methods of use thereof
US20130028925A1 (en) 2006-12-28 2013-01-31 Harvey Friedman Herpes simplex virus combined subunit vaccines and methods of use thereof
CA2816925C (en) 2009-11-04 2023-01-10 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
US20180303925A1 (en) 2015-04-27 2018-10-25 The Trustees Of The University Of Pennsylvania Nucleoside-Modified RNA For Inducing an Adaptive Immune Response
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
MA49463A (en) * 2017-04-26 2021-05-05 Modernatx Inc HERPES SIMPLEX VACCINE
CN111246854A (en) 2017-08-17 2020-06-05 宾夕法尼亚大学理事会 Modified mRNA vaccine encoding herpes simplex virus glycoprotein and use thereof
EP4444345A2 (en) * 2021-12-08 2024-10-16 ModernaTX, Inc. Herpes simplex virus mrna vaccines
CA3242744A1 (en) * 2022-01-27 2023-08-03 The Trustees Of The University Of Pennsylvania Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
EP4654996A1 (en) * 2023-01-27 2025-12-03 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein c, glycoprotein d, and glycoprotein e antigens and related methods

Also Published As

Publication number Publication date
WO2025030134A1 (en) 2025-02-06
AU2024318951A1 (en) 2026-03-12
CN121866069A (en) 2026-04-14

Similar Documents

Publication Publication Date Title
WO2023107999A3 (en) Herpes simplex virus mrna vaccines
EP4242223A3 (en) Modified mrna vaccines encoding herpes simplex virus glycoproteins and uses thereof
WO2008099189A3 (en) Herpes simplex viruses and methods of viral replication
MX342639B (en) High titer recombinant influenza viruses for vaccines and gene therapy.
IL326351A (en) Rna compositions encoding herpes simplex virus glycoprotein b antigens and uses thereof
IL188362A0 (en) Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
AU2003246373A1 (en) Recombinant measles viruses expressing epitopes pf antigens of rna viruses and use of the recombinant viruses for the preparation of vaccine compositions
IL216508A (en) Vaccines against herpes simplex virus type 1 and/or type 2 and compositions and uses thereof
WO2007044024A3 (en) Recombinant influenza vectors with tandem transcription units
WO2006083286A3 (en) Genetically engineered swine influenza virus and uses thereof
ZA202206789B (en) Varicella-zoster virus vaccine and application thereof
WO2006088481A3 (en) Genetically engineered equine influenza virus and uses thereof
PT1053017E (en) VACCINES UNDERSTANDING INTERLEUCIN-12 AND HERPES SIMPLEX VIRUS ANTIGEN
WO2020028719A3 (en) Compositions comprising herpes simplex virus-1 for use in methods of treating and preventing cancer
ZA202305129B (en) Recombinant hvt and uses thereof
IL314324A (en) Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
MX2024004293A (en) Combination of novel vaccines against zika virus and dna antibody constructs for use against zika virus.
IL326358A (en) Rna compositions encoding herpes simplex virus glycoprotein e and/or glycoprotein i antigens and uses thereof
WO2009120339A3 (en) Vectors for delivering disease neutralizing agents
CA3300517A1 (en) Rna compositions encoding herpes simplex virus glycoprotein e and/or glycoprotein i antigens and uses thereof
CA3300532A1 (en) Rna compositions encoding herpes simplex virus glycoprotein b antigens and uses thereof
EP1731599A4 (en) Method of constructing recombinant herpes simplex virus
WO2005012538A3 (en) Accelerated vaccination
AU8467201A (en) Compositions for and methods of using herpes simplex virus glycoprotein d to suppress immune responses
WO2005056051A3 (en) Hepatitis b vaccines and compositions